A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

Phase 2

Completed

• Conditions: Breast Neoplasms

• Registration Number: NCT00078000
• Lead Sponsor: Pfizer

Brief Summary

Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2004-02-13
• Study First Submitted QC: 2004-02-17
• Study First Posted: 2004-02-18
• Study Start: 2004-03
• Study Completion: 2005-11
• Status Verified: 2008-11
• Last Update Submitted: 2008-11-24
• Last Update Posted: 2008-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• Anthracycline and taxane-refractory or intolerant metastatic breast cancer
• Female

Exclusion Criteria

• Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Anti-tumor efficacy

Secondary Outcome Measures

Name	Time	Method
Tumor control survival safety pharmacokinetics

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Boston, Massachusetts, United States